-+ 0.00%
-+ 0.00%
-+ 0.00%
Evaxion Publishes Q3 2026 Results and Strategy Update Transcript
Share
Listen to the news
Evaxion Publishes Q3 2026 Results and Strategy Update Transcript
  • Evaxion is redirecting its own resources to oncology, prioritizing cancer vaccines while seeking partners for infectious disease assets.
  • The November 19, 2026, third-quarter results call featured CEO Helen Tayton-Martin, CSO/COO Birgitte Rono, CFO Thomas Schmidt and analysts.
  • Management expects to file the EVX-04 clinical trial application by year-end; expansion of EVX-01 beyond advanced melanoma will likely involve partnerships.
  • Cash runway now extends toward the end of 2027, supported by ATM proceeds; expected annual cash burn remains approximately $14 million.
  • Quarterly net loss totaled $3.5 million versus a $4.6 million year-earlier profit, reflecting no recognized revenue versus prior-year EVX-B3 licensing revenue.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending